Swedbank AB Has $44.70 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Swedbank AB reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 23.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 334,517 shares of the life sciences company’s stock after selling 101,359 shares during the quarter. Swedbank AB’s holdings in Illumina were worth $44,702,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ILMN. Massachusetts Financial Services Co. MA boosted its position in shares of Illumina by 148.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock worth $137,735,000 after buying an additional 631,294 shares during the period. Janus Henderson Group PLC boosted its position in Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. Iron Triangle Partners LP acquired a new position in Illumina during the third quarter valued at approximately $57,380,000. FMR LLC boosted its position in Illumina by 127.3% during the third quarter. FMR LLC now owns 767,294 shares of the life sciences company’s stock valued at $100,063,000 after purchasing an additional 429,723 shares during the last quarter. Finally, PointState Capital LP acquired a new position in Illumina during the third quarter valued at approximately $39,420,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently commented on ILMN shares. Stephens increased their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research report on Tuesday, November 5th. TD Cowen increased their price target on Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Barclays upped their price objective on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

Illumina Price Performance

Illumina stock opened at $131.72 on Thursday. The stock’s fifty day moving average price is $139.05 and its two-hundred day moving average price is $135.07. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The firm has a market cap of $20.89 billion, a PE ratio of -13.22 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the company earned $0.33 EPS. The company’s revenue was down 3.5% on a year-over-year basis. As a group, research analysts expect that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.